Biomunex Pharmaceuticals Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 6

Biomunex Pharmaceuticals General Information

Description

Developer of immunotherapies designed to deliver therapeutics in the area of oncology. The company's immunotherapies offer to develop drug candidates with high anti-tumor potential, superior manufacturability, and optimal drug-like properties, enabling biotechnology companies to format antibodies from any pair of monospecific monoclonal antibodies as building blocks in a timely and cost-effective manner.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 101 / 103 boulevard Murat
  • 75016 Paris
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 101 / 103 boulevard Murat
  • 75016 Paris
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biomunex Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 01-Oct-2025 Completed Generating Revenue
7. Grant 03-Nov-2021 Completed Generating Revenue
6. Later Stage VC (Series A) 16-Feb-2021 Completed Generating Revenue
5. Seed Round Completed Startup
4. Accelerator/Incubator Completed Startup
3. Grant 01-Jan-2016 Completed Startup
2. Grant 01-Jan-2014 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Biomunex Pharmaceuticals’s complete valuation and funding history, request access »

Biomunex Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
To view Biomunex Pharmaceuticals’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Biomunex Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immunotherapies designed to deliver therapeutics in the area of oncology. The company's immunotherapies off
Drug Discovery
Paris, France
13 As of 2025

New York, NY
 

Barcelona, Spain
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biomunex Pharmaceuticals Competitors (10)

One of Biomunex Pharmaceuticals’s 10 competitors is Volastra, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Volastra Venture Capital-Backed New York, NY
Ona Therapeutics Venture Capital-Backed Barcelona, Spain
Ability Pharma Private Equity-Backed Cerdanyola, Spain
Genentech Formerly VC-backed South San Francisco, CA
Savara Formerly VC-backed Yardley, PA
You’re viewing 5 of 10 competitors. Get the full list »

Biomunex Pharmaceuticals Patents

Biomunex Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026180674-A1 Antibodies specific to va7.2 domain of mucosal associated invariant t (mait) cells Pending 28-Feb-2025
WO-2026068750-A1 Antibodies that specifically bind mucosal associated invariant t (mait) cells Pending 27-Sep-2024
AU-2023228330-A1 Bispecific antibodies binding to her-3 and to either her-2 or egfr Pending 02-Mar-2022
EP-4486774-A1 Bispecific antibodies binding to her-3 and to either her-2 or egfr Pending 02-Mar-2022
US-20250282892-A1 Bispecific antibodies binding to her-3 and to either her-2 or egfr Pending 02-Mar-2022 C07K16/32
To view Biomunex Pharmaceuticals’s complete patent history, request access »

Biomunex Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biomunex Pharmaceuticals Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eurobail Formation Corporation Minority
French Government Government
Onward Therapeutics VC-Backed Company Minority
L'Agence Nationale de la Recherche Government
Bpifrance Sovereign Wealth Fund
You’re viewing 5 of 6 investors. Get the full list »

Biomunex Pharmaceuticals FAQs

  • When was Biomunex Pharmaceuticals founded?

    Biomunex Pharmaceuticals was founded in 2014.

  • Where is Biomunex Pharmaceuticals headquartered?

    Biomunex Pharmaceuticals is headquartered in Paris, France.

  • What is the size of Biomunex Pharmaceuticals?

    Biomunex Pharmaceuticals has 13 total employees.

  • What industry is Biomunex Pharmaceuticals in?

    Biomunex Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Biomunex Pharmaceuticals a private or public company?

    Biomunex Pharmaceuticals is a Private company.

  • What is Biomunex Pharmaceuticals’s current revenue?

    The current revenue for Biomunex Pharmaceuticals is .

  • How much funding has Biomunex Pharmaceuticals raised over time?

    Biomunex Pharmaceuticals has raised $6.41M.

  • Who are Biomunex Pharmaceuticals’s investors?

    Eurobail Formation, French Government, Onward Therapeutics, L'Agence Nationale de la Recherche, and Bpifrance are 5 of 6 investors who have invested in Biomunex Pharmaceuticals.

  • Who are Biomunex Pharmaceuticals’s competitors?

    Volastra, Ona Therapeutics, Ability Pharma, Genentech, and Savara are some of the 10 competitors of Biomunex Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process